Onglyza saxagliptin regulatory update

Bristol-Myers and AstraZeneca said FDA extended the PDUFA data for an NDA for Onglyza saxagliptin to treat Type II diabetes to July 30 from April 30. Bristol-Myers said the agency did not give a reaso...